| pubmed-article:19204207 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19204207 | lifeskim:mentions | umls-concept:C1257890 | lld:lifeskim |
| pubmed-article:19204207 | lifeskim:mentions | umls-concept:C1516985 | lld:lifeskim |
| pubmed-article:19204207 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
| pubmed-article:19204207 | lifeskim:mentions | umls-concept:C0017636 | lld:lifeskim |
| pubmed-article:19204207 | lifeskim:mentions | umls-concept:C0006118 | lld:lifeskim |
| pubmed-article:19204207 | lifeskim:mentions | umls-concept:C0007257 | lld:lifeskim |
| pubmed-article:19204207 | lifeskim:mentions | umls-concept:C0076080 | lld:lifeskim |
| pubmed-article:19204207 | lifeskim:mentions | umls-concept:C0034897 | lld:lifeskim |
| pubmed-article:19204207 | lifeskim:mentions | umls-concept:C1135135 | lld:lifeskim |
| pubmed-article:19204207 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:19204207 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:19204207 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:19204207 | pubmed:dateCreated | 2009-3-9 | lld:pubmed |
| pubmed-article:19204207 | pubmed:abstractText | Approximately 50% of glioblastomas (GBMs) are characterized by overexpression of the epidermal growth factor receptor (EGFR) and EGFR gene amplification. In approximately 25% of instances, constitutively activated EGFR mutants are present. These observations make EGFR-inhibiting drugs a logical approach for trials in recurrent GBM. | lld:pubmed |
| pubmed-article:19204207 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19204207 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19204207 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19204207 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19204207 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19204207 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19204207 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19204207 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19204207 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19204207 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19204207 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19204207 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19204207 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19204207 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19204207 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19204207 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19204207 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19204207 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19204207 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19204207 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19204207 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19204207 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19204207 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19204207 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19204207 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19204207 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19204207 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19204207 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19204207 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19204207 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19204207 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19204207 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19204207 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19204207 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19204207 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19204207 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19204207 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19204207 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19204207 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19204207 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:19204207 | pubmed:issn | 1527-7755 | lld:pubmed |
| pubmed-article:19204207 | pubmed:author | pubmed-author:FrenayMarcM | lld:pubmed |
| pubmed-article:19204207 | pubmed:author | pubmed-author:KrosJohan MJM | lld:pubmed |
| pubmed-article:19204207 | pubmed:author | pubmed-author:CamponeMarioM | lld:pubmed |
| pubmed-article:19204207 | pubmed:author | pubmed-author:BrandesAlba... | lld:pubmed |
| pubmed-article:19204207 | pubmed:author | pubmed-author:TaphoornMarti... | lld:pubmed |
| pubmed-article:19204207 | pubmed:author | pubmed-author:GorliaThierry... | lld:pubmed |
| pubmed-article:19204207 | pubmed:author | pubmed-author:CarpentierAnt... | lld:pubmed |
| pubmed-article:19204207 | pubmed:author | pubmed-author:van den... | lld:pubmed |
| pubmed-article:19204207 | pubmed:author | pubmed-author:TosoniAliciaA | lld:pubmed |
| pubmed-article:19204207 | pubmed:author | pubmed-author:LacombeDenisD | lld:pubmed |
| pubmed-article:19204207 | pubmed:author | pubmed-author:RamplingRoyR | lld:pubmed |
| pubmed-article:19204207 | pubmed:author | pubmed-author:BaurainJean-F... | lld:pubmed |
| pubmed-article:19204207 | pubmed:author | pubmed-author:KouwenhovenMa... | lld:pubmed |
| pubmed-article:19204207 | pubmed:author | pubmed-author:KlughammerBar... | lld:pubmed |
| pubmed-article:19204207 | pubmed:author | pubmed-author:ClementPaul... | lld:pubmed |
| pubmed-article:19204207 | pubmed:author | pubmed-author:ArmandJean-Pa... | lld:pubmed |
| pubmed-article:19204207 | pubmed:author | pubmed-author:KletzlHeidema... | lld:pubmed |
| pubmed-article:19204207 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19204207 | pubmed:day | 10 | lld:pubmed |
| pubmed-article:19204207 | pubmed:volume | 27 | lld:pubmed |
| pubmed-article:19204207 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19204207 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19204207 | pubmed:pagination | 1268-74 | lld:pubmed |
| pubmed-article:19204207 | pubmed:dateRevised | 2010-9-23 | lld:pubmed |
| pubmed-article:19204207 | pubmed:meshHeading | pubmed-meshheading:19204207... | lld:pubmed |
| pubmed-article:19204207 | pubmed:meshHeading | pubmed-meshheading:19204207... | lld:pubmed |
| pubmed-article:19204207 | pubmed:meshHeading | pubmed-meshheading:19204207... | lld:pubmed |
| pubmed-article:19204207 | pubmed:meshHeading | pubmed-meshheading:19204207... | lld:pubmed |
| pubmed-article:19204207 | pubmed:meshHeading | pubmed-meshheading:19204207... | lld:pubmed |
| pubmed-article:19204207 | pubmed:meshHeading | pubmed-meshheading:19204207... | lld:pubmed |
| pubmed-article:19204207 | pubmed:meshHeading | pubmed-meshheading:19204207... | lld:pubmed |
| pubmed-article:19204207 | pubmed:meshHeading | pubmed-meshheading:19204207... | lld:pubmed |
| pubmed-article:19204207 | pubmed:meshHeading | pubmed-meshheading:19204207... | lld:pubmed |
| pubmed-article:19204207 | pubmed:meshHeading | pubmed-meshheading:19204207... | lld:pubmed |
| pubmed-article:19204207 | pubmed:meshHeading | pubmed-meshheading:19204207... | lld:pubmed |
| pubmed-article:19204207 | pubmed:meshHeading | pubmed-meshheading:19204207... | lld:pubmed |
| pubmed-article:19204207 | pubmed:meshHeading | pubmed-meshheading:19204207... | lld:pubmed |
| pubmed-article:19204207 | pubmed:meshHeading | pubmed-meshheading:19204207... | lld:pubmed |
| pubmed-article:19204207 | pubmed:meshHeading | pubmed-meshheading:19204207... | lld:pubmed |
| pubmed-article:19204207 | pubmed:meshHeading | pubmed-meshheading:19204207... | lld:pubmed |
| pubmed-article:19204207 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19204207 | pubmed:articleTitle | Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. | lld:pubmed |
| pubmed-article:19204207 | pubmed:affiliation | Neuro-Oncology Unit, Daniel den Hoed Cancer Center, PO Box 5201, 3008AE Rotterdam, the Netherlands. m.vandenbent@erasmusmc.nl | lld:pubmed |
| pubmed-article:19204207 | pubmed:publicationType | Journal Article | lld:pubmed |
